These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 9338081)

  • 1. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid.
    Kelly JW; Colon W; Lai Z; Lashuel HA; McCulloch J; McCutchen SL; Miroy GJ; Peterson SA
    Adv Protein Chem; 1997; 50():161-81. PubMed ID: 9338081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FAP mutations destabilize transthyretin facilitating conformational changes required for amyloid formation.
    Colon W; Lai Z; McCutchen SL; Miroy GJ; Strang C; Kelly JW
    Ciba Found Symp; 1996; 199():228-38; discussion 239-42. PubMed ID: 8915613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation.
    Lashuel HA; Lai Z; Kelly JW
    Biochemistry; 1998 Dec; 37(51):17851-64. PubMed ID: 9922152
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid.
    Lai Z; Colón W; Kelly JW
    Biochemistry; 1996 May; 35(20):6470-82. PubMed ID: 8639594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of lethal and nonlethal transthyretin variants and their relationship to amyloid disease.
    McCutchen SL; Lai Z; Miroy GJ; Kelly JW; Colón W
    Biochemistry; 1995 Oct; 34(41):13527-36. PubMed ID: 7577941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions.
    Lashuel HA; Wurth C; Woo L; Kelly JW
    Biochemistry; 1999 Oct; 38(41):13560-73. PubMed ID: 10521263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Initial conformational changes of human transthyretin under partially denaturing conditions.
    Yang M; Lei M; Bruschweiler R; Huo S
    Biophys J; 2005 Jul; 89(1):433-43. PubMed ID: 15821170
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured.
    Jiang X; Smith CS; Petrassi HM; Hammarström P; White JT; Sacchettini JC; Kelly JW
    Biochemistry; 2001 Sep; 40(38):11442-52. PubMed ID: 11560492
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro.
    Colon W; Kelly JW
    Biochemistry; 1992 Sep; 31(36):8654-60. PubMed ID: 1390650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibiting transthyretin amyloid fibril formation via protein stabilization.
    Miroy GJ; Lai Z; Lashuel HA; Peterson SA; Strang C; Kelly JW
    Proc Natl Acad Sci U S A; 1996 Dec; 93(26):15051-6. PubMed ID: 8986762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetramer dissociation and monomer partial unfolding precedes protofibril formation in amyloidogenic transthyretin variants.
    Quintas A; Vaz DC; Cardoso I; Saraiva MJ; Brito RM
    J Biol Chem; 2001 Jul; 276(29):27207-13. PubMed ID: 11306576
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Search for intermediate structures in transthyretin fibrillogenesis: soluble tetrameric Tyr78Phe TTR expresses a specific epitope present only in amyloid fibrils.
    Redondo C; Damas AM; Olofsson A; Lundgren E; Saraiva MJ
    J Mol Biol; 2000 Dec; 304(3):461-70. PubMed ID: 11090287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and structural analysis of halogen substituted fibril formation inhibitors of Human Transthyretin (TTR).
    Ciccone L; Nencetti S; Rossello A; Stura EA; Orlandini E
    J Enzyme Inhib Med Chem; 2016; 31(sup1):40-51. PubMed ID: 27067161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. R104H may suppress transthyretin amyloidogenesis by thermodynamic stabilization, but not by the kinetic mechanism characterizing T119 interallelic trans-suppression.
    Sekijima Y; Dendle MT; Wiseman RL; White JT; D'Haeze W; Kelly JW
    Amyloid; 2006 Jun; 13(2):57-66. PubMed ID: 16911959
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transthyretin amyloidosis: a tale of weak interactions.
    Saraiva MJ
    FEBS Lett; 2001 Jun; 498(2-3):201-3. PubMed ID: 11412857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentially amyloidogenic conformational intermediates populate the unfolding landscape of transthyretin: insights from molecular dynamics simulations.
    Rodrigues JR; Simões CJ; Silva CG; Brito RM
    Protein Sci; 2010 Feb; 19(2):202-19. PubMed ID: 19937650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The amyloidogenic potential of transthyretin variants correlates with their tendency to aggregate in solution.
    Quintas A; Saraiva MJ; Brito RM
    FEBS Lett; 1997 Dec; 418(3):297-300. PubMed ID: 9428731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synthesis and characterization of potent bivalent amyloidosis inhibitors that bind prior to transthyretin tetramerization.
    Green NS; Palaninathan SK; Sacchettini JC; Kelly JW
    J Am Chem Soc; 2003 Nov; 125(44):13404-14. PubMed ID: 14583036
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chromium(III) ion and thyroxine cooperate to stabilize the transthyretin tetramer and suppress in vitro amyloid fibril formation.
    Sato T; Ando Y; Susuki S; Mikami F; Ikemizu S; Nakamura M; Suhr O; Anraku M; Kai T; Suico MA; Shuto T; Mizuguchi M; Yamagata Y; Kai H
    FEBS Lett; 2006 Jan; 580(2):491-6. PubMed ID: 16386248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conformational Dynamics of an Amyloidogenic Intermediate of Transthyretin: Implications for Structural Remodeling and Amyloid Formation.
    Leach BI; Ferguson JA; Morgan G; Sun X; Kroon G; Oyen D; Dyson HJ; Wright PE
    J Mol Biol; 2024 Aug; 436(16):168673. PubMed ID: 38909653
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.